MyLab X75 Ultrasound System Launches Reports Esaote: Enriched with Unparalleled Connectivity and Image Sharing Tools

MyLab X75 offers access to specific clinical solutions such as micro-vascularization assessment, liver stiffness quantification as well as zero-click left ventricle function analysis to always deliver the best care possible.

Esaote, located in Genoa, Italy mission is to obtain extremely clear, easy-to-read ultrasound images to ensure accurate diagnosis in the shortest time possible, enhancing the users’ experience across several clinical applications.

“In the world of imaging and non-invasive diagnostics innovation is key,” says Eugenio Biglieri, Esaote COO. “Particularly now that health organizations are under great pressure, ultrasound imaging can give a very important contribution, due to non-ionizing-radiation, agile and point-of-care approach, which ensure accessibility. In this scenario ease of use and automation are the main drivers for the technology’s adoption.”

MyLab X75 is enriched with unparalleled connectivity and image sharing tools, which clearly facilitate the system management in this challenging pandemic period and allow innovative models to be implemented.

“Voice of the customers and consolidated experience were at the core of MyLab X75’s development,” says Giovanni Altobelli, Global Marketing Product Manager, “and making ultrasound imaging easier was our first priority: light and agile, ergonomic and silent, productive and eco-friendly, the new system perfectly meets nowadays clinical needs.”

MyLab X75 is being unveiled on Friday, May 28, 2021 with an exclusive streaming event on several platforms. The event, part of the Esaote’s “Exploring the inside” program, is dedicated to the theme of Experience. Distinguished guests such as the professional alpinist Hervé Barmasse and emeritus medical experts participate in and contribute to the event.

SourceEsaote

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”